Dec 24 (Reuters) - Britain's FTSE 100 index is

seen opening higher on Tuesday, with futures up 0.22%.

* ANGLO AMERICAN: Chile's environmental regulator has filed

four charges against the major Los Bronces copper mine,

controlled by Anglo American, for noncompliance with

environmental permits, the agency said on Monday.

* HIKMA: The U.S. Food and Drug Administration on Monday

approved Hikma Pharmaceuticals' ( HKMPF ) generic version of Novo

Nordisk's diabetes drug Victoza, clearing the way for

the launch of another copy of the treatment in the country.

* NHS: Eli Lilly's ( LLY ) obesity drug Mounjaro will be

available through Britain's state health system for some

patients from March, after the drugs cost-effectiveness watchdog

NICE on Monday gave its approval.

* COVID ANITOBDY DRUGS: The U.S. Food and Drug

Administration has revoked the emergency use authorization for

four COVID-19 antibody-based drugs, including those from

AstraZeneca ( AZN ) and GSK.

* OIL: Oil prices rose on Tuesday, reversing the prior

session's losses, buoyed by slightly positive market outlook for

the short term and stronger U.S. economic data, despite thin

trade ahead of the Christmas holiday.

* METALS: Most base metals rose in tight ranges on Tuesday

but the strength of the dollar, driven by the prospect of

higher-for-longer U.S. interest rates, limited their gains.

* GOLD: Gold prices edged higher on Tuesday, as investors

braced for a less aggressive path of interest rate cuts from the

Federal Reserve next year, in a holiday-truncated trading week.

* Britain's benchmark FTSE 100 kicked off a

holiday-shortened week on a higher note on Monday, while

investors analysed data that showed the British economy

flat-lined in the third quarter of the year.

* For more on the factors affecting European stocks, please

click on:

TODAY'S UK PAPERS

> Financial Times

> Other business headlines

(Reporting by Yamini Kalia in Bengaluru)